ReviewRadiation oncology (London, England)2020

Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy.

Lukas Käsmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.